405 related articles for article (PubMed ID: 22056763)
21. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD).
Ahmed MH; Byrne CD
Drug Discov Today; 2007 Sep; 12(17-18):740-7. PubMed ID: 17826687
[TBL] [Abstract][Full Text] [Related]
22. Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities.
Musso G; Cassader M; Cohney S; De Michieli F; Pinach S; Saba F; Gambino R
Diabetes Care; 2016 Oct; 39(10):1830-45. PubMed ID: 27660122
[TBL] [Abstract][Full Text] [Related]
23. Adiponectin and PPAR: a setup for intricate crosstalk between obesity and non-alcoholic fatty liver disease.
Ishtiaq SM; Rashid H; Hussain Z; Arshad MI; Khan JA
Rev Endocr Metab Disord; 2019 Sep; 20(3):253-261. PubMed ID: 31656991
[TBL] [Abstract][Full Text] [Related]
24. Exploring the Regulatory Role of ncRNA in NAFLD: A Particular Focus on PPARs.
Mukherjee AG; Wanjari UR; Gopalakrishnan AV; Katturajan R; Kannampuzha S; Murali R; Namachivayam A; Ganesan R; Renu K; Dey A; Vellingiri B; Prince SE
Cells; 2022 Dec; 11(24):. PubMed ID: 36552725
[TBL] [Abstract][Full Text] [Related]
25. The liver X receptor: a master regulator of the gut-liver axis and a target for non alcoholic fatty liver disease.
Ducheix S; Montagner A; Theodorou V; Ferrier L; Guillou H
Biochem Pharmacol; 2013 Jul; 86(1):96-105. PubMed ID: 23542537
[TBL] [Abstract][Full Text] [Related]
26. Review article: vascular effects of PPARs in the context of NASH.
Guixé-Muntet S; Biquard L; Szabo G; Dufour JF; Tacke F; Francque S; Rautou PE; Gracia-Sancho J
Aliment Pharmacol Ther; 2022 Jul; 56(2):209-223. PubMed ID: 35661191
[TBL] [Abstract][Full Text] [Related]
27. PPARs as Metabolic Regulators in the Liver: Lessons from Liver-Specific PPAR-Null Mice.
Wang Y; Nakajima T; Gonzalez FJ; Tanaka N
Int J Mol Sci; 2020 Mar; 21(6):. PubMed ID: 32192216
[TBL] [Abstract][Full Text] [Related]
28. PPARs at the crossroads of lipid signaling and inflammation.
Wahli W; Michalik L
Trends Endocrinol Metab; 2012 Jul; 23(7):351-63. PubMed ID: 22704720
[TBL] [Abstract][Full Text] [Related]
29. The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD.
Dixon ED; Nardo AD; Claudel T; Trauner M
Genes (Basel); 2021 Apr; 12(5):. PubMed ID: 33926085
[TBL] [Abstract][Full Text] [Related]
30. Long-term combination therapy of ezetimibe and acarbose for non-alcoholic fatty liver disease.
Nozaki Y; Fujita K; Yoneda M; Wada K; Shinohara Y; Takahashi H; Kirikoshi H; Inamori M; Kubota K; Saito S; Mizoue T; Masaki N; Nagashima Y; Terauchi Y; Nakajima A
J Hepatol; 2009 Sep; 51(3):548-56. PubMed ID: 19596472
[TBL] [Abstract][Full Text] [Related]
31. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease.
Kallwitz ER; McLachlan A; Cotler SJ
World J Gastroenterol; 2008 Jan; 14(1):22-8. PubMed ID: 18176957
[TBL] [Abstract][Full Text] [Related]
32. Evolving therapies for non-alcoholic steatohepatitis.
Tilg H; Moschen AR
Expert Opin Drug Discov; 2014 Jun; 9(6):687-96. PubMed ID: 24766298
[TBL] [Abstract][Full Text] [Related]
33. The Role of Nuclear Receptors in the Pathogenesis and Treatment of Non-alcoholic Fatty Liver Disease.
Yang Z; Danzeng A; Liu Q; Zeng C; Xu L; Mo J; Pingcuo C; Wang X; Wang C; Zhang B; Zhang B
Int J Biol Sci; 2024; 20(1):113-126. PubMed ID: 38164174
[TBL] [Abstract][Full Text] [Related]
34. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans.
Ballestri S; Nascimbeni F; Romagnoli D; Baldelli E; Lonardo A
Adv Ther; 2016 Mar; 33(3):291-319. PubMed ID: 26921205
[TBL] [Abstract][Full Text] [Related]
35. The role of apolipoprotein A5 in non-alcoholic fatty liver disease.
Ress C; Moschen AR; Sausgruber N; Tschoner A; Graziadei I; Weiss H; Schgoer W; Ebenbichler CF; Konrad RJ; Patsch JR; Tilg H; Kaser S
Gut; 2011 Jul; 60(7):985-91. PubMed ID: 21339203
[TBL] [Abstract][Full Text] [Related]
36. Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis.
Han X; Wu Y; Yang Q; Cao G
Pharmacol Ther; 2021 Jun; 222():107791. PubMed ID: 33321113
[TBL] [Abstract][Full Text] [Related]
37. Peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms in nonalcoholic fatty liver disease: a study in Brazilian patients.
Domenici FA; Brochado MJ; Martinelli Ade L; Zucoloto S; da Cunha SF; Vannucchi H
Gene; 2013 Oct; 529(2):326-31. PubMed ID: 23891824
[TBL] [Abstract][Full Text] [Related]
38. Pleiotropic Actions of Peroxisome Proliferator-Activated Receptors (PPARs) in Dysregulated Metabolic Homeostasis, Inflammation and Cancer: Current Evidence and Future Perspectives.
Laganà AS; Vitale SG; Nigro A; Sofo V; Salmeri FM; Rossetti P; Rapisarda AM; La Vignera S; Condorelli RA; Rizzo G; Buscema M
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27347932
[TBL] [Abstract][Full Text] [Related]
39. The transrepressive activity of peroxisome proliferator-activated receptor alpha is necessary and sufficient to prevent liver fibrosis in mice.
Pawlak M; Baugé E; Bourguet W; De Bosscher K; Lalloyer F; Tailleux A; Lebherz C; Lefebvre P; Staels B
Hepatology; 2014 Nov; 60(5):1593-606. PubMed ID: 24995693
[TBL] [Abstract][Full Text] [Related]
40. Non-alcoholic fatty liver disease.
Leclercq I
Bull Mem Acad R Med Belg; 2010; 165(3-4):147-55; discussion 155-8. PubMed ID: 21166266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
